Acta haematologica · 2026
Eltrombopag-Induced Serum Pigmentation in Severe Aplastic Anemia: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Desbrousses Eva, Charbonnel Tifenn, Arbion Flavie, Alarcan Hugo, Vallet Nicolas
Аннотация
INTRODUCTION: Severe aplastic anemia (SAA) is a bone marrow failure disorder characterized by profound pancytopenia associated with a high risk of infection and bleeding.
CASE PRESENTATION: We report a case of a 19-year-old patient with a history of acute hepatitis who was admitted to the hospital with acquired SAA attested by 2% cellularity at bone marrow trephine biopsy. In the absence of matched sibling donor, immunosuppressive therapy with horse anti-thymocyte globulin, cyclosporine, and eltrombopag was initiated. Following centrifugation, serum obtained from blood samples addressed to the laboratory displayed a rare manifestation of brown color. Intravascular hemolysis was excluded based on normal haptoglobin and lactate dehydrogenase ranges, although bilirubin was mildly elevated. The brown staining disappeared after therapy discontinuation. Eltrombopag is a chromogenic molecule which absorbs visible light associated with serum coloration.
CONCLUSION: This rare case highlights drug-induced serum pigmentation as a surprising manifestation in patients receiving eltrombopag and its normalization following drug withdrawal.
CASE PRESENTATION: We report a case of a 19-year-old patient with a history of acute hepatitis who was admitted to the hospital with acquired SAA attested by 2% cellularity at bone marrow trephine biopsy. In the absence of matched sibling donor, immunosuppressive therapy with horse anti-thymocyte globulin, cyclosporine, and eltrombopag was initiated. Following centrifugation, serum obtained from blood samples addressed to the laboratory displayed a rare manifestation of brown color. Intravascular hemolysis was excluded based on normal haptoglobin and lactate dehydrogenase ranges, although bilirubin was mildly elevated. The brown staining disappeared after therapy discontinuation. Eltrombopag is a chromogenic molecule which absorbs visible light associated with serum coloration.
CONCLUSION: This rare case highlights drug-induced serum pigmentation as a surprising manifestation in patients receiving eltrombopag and its normalization following drug withdrawal.